Clinical trial · Interventional
Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors
Construction of a Multi-mode Ablation Treatment System and Molecular Imaging Multi-omics Study for Malignant Liver Tumors of Digestive System Origin
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This single-center, parallel-controlled clinical trial aims to establish a multi-mode ablation system for liver malignant tumors originating from the digestive system. The study will evaluate the safety and efficacy of multi-mode tumor ablation, utilizing a multi-mode imaging platform for ablation planning and immediate evaluation of intraoperative ablation effects. Additionally, the study will employ multi-omics and multi-mode imaging techniques to explore the spatiotemporal heterogeneity and immune escape mechanisms of liver metastases from gastrointestinal tumors, providing guidance for treatment strategy formulation and prognostic evaluation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Liver Metastases | — | UNRESOLVED | — |
| Primary Liver Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multi-mode tumor treatment system | Device | — | UNRESOLVED |
| Radiofrequency ablation therapeutic apparatus | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Multi-mode Ablation
- description
- This arm includes patients with primary liver cancer or colorectal cancer liver metastasis (five cases each, totaling ten cases) who will receive multi-mode ablation, a novel ablation therapy that combines cryoablation and radiofrequency ablation.
- interventionNames
- Device: Multi-mode tumor treatment system
- type
- ACTIVE_COMPARATOR
- label
- Conventional Radiofrequency Ablation
- description
- This arm includes patients with primary liver cancer or colorectal cancer liver metastasis (five cases each, totaling ten cases) who will receive conventional radiofrequency ablation treatment.
- interventionNames
- Device: Radiofrequency ablation therapeutic apparatus
Primary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18 and 75 years, gender not specified; 2. Pathologically confirmed primary liver cancer or colorectal cancer liver metastases, which is unresectable, intolerant to surgical resection, or refused surgical resection; 3. Intrahepatic lesions with a diameter of ≤4cm, and the number of lesions ≤3.; 4. At least 3 months since the last systemic treatment and at least 1 month since the last local treatment; 5. Child-Pugh class A or B; 6. ECOG PS ≤ 2. Exclusion Criteria: 1. Liver function Child-Pugh class C , severe jaundice, especially obstructive jaundice; 2. Diffuse liver cancer, or with tumor thrombi in the main portal vein to secondary branches or hepatic vein; 3. Significant liver atrophy, tumor volume too large, requiring ablation range of up to one-third of the liver volume; 4. Multiple systemic metastases, expected survival \< 3 months; 5. Recent history of esophageal (gastric fundus) variceal bleeding within the past month; 6. Severe functional failure of major organs such as the liver, kidneys, heart, lungs or brain; 7. Presence of active infection; 8. Uncorrectable coagulation dysfunction and severe hematological abnormalities, with a significant bleeding tendency; 9. Refractory massive ascites, pleural effusion, or cachexia; 10. Pregnancy, disorder or inability to cooperate with treatment; 11. Any other factors deemed inappropriate for inclusion or affecting the subject's participation in the study, as determined by the investigators.
References
Publications (0)
Data not yet available